GlassScriptPhysician profile
Jaclyn Thoresz
NPI 1558399337
$15,238.71
in general payments reported to CMS, 2019-2025
29 companies · $3,101 in 2025
The $3,101 reported for 2025 was more than what 97% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,716 · 2022: $3,310 · 2023: $3,226 · 2024: $2,884 · 2025: $3,101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,659 · Consulting Fee: $400 · Education: $153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,659.26 |
| Consulting Fee | $400.00 |
| Education | $152.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,597.26 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $2,499.27 | 2021-2025 | Airsupra, Fasenra, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,854.17 | 2021-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Actelion Pharmaceuticals US, INC. | $1,525.01 | 2021-2025 | Opsumit, Uptravi |
| Regeneron Healthcare Solutions, INC. | $1,048.18 | 2021-2025 | Dupixent |
| Genzyme Corporation | $776.56 | 2021-2025 | |
| Baxter Healthcare | $749.58 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System, Hillrom - Monarch Airway Clearance System |
| Mylan Specialty L.P. | $517.70 | 2021-2024 | Yupelri |
| Amgen INC. | $441.64 | 2021-2025 | Tezspire |
| Verona Pharma, INC. | $367.98 | 2025 | Ohtuvayre |
| Electromed, INC. | $354.45 | 2021-2024 | Smartvest |
| Philips North America LLC | $352.73 | 2021-2024 | (Ak6) Vest Therapy |
| Genentech USA, INC. | $297.40 | 2022-2024 | Xolair |
| Novartis Pharmaceuticals Corporation | $288.34 | 2021-2025 | |
| United Therapeutics Corporation | $254.20 | 2021-2025 | Tyvaso, Tyvaso |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $190.66 | 2022-2025 | Arikayce |
| Mallinckrodt Hospital Products INC. | $160.72 | 2021-2023 | Acthar |
| Viatris Specialty LLC | $142.00 | 2025 | Yupelri |
| Advanced Respiratory, INC | $141.49 | 2021 | |
| Merck Sharp & Dohme LLC | $135.04 | 2022-2025 | Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $130.60 | 2021-2024 | |
| Grifols USA, LLC | $124.67 | 2021-2025 | Prolastin-C Liquid |
| Sanofi-Aventis U.S. LLC | $94.95 | 2023 | |
| Inogen, INC. | $54.82 | 2023-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Pfizer INC. | $45.14 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.48 | 2022 | |
| Shionogi INC | $23.89 | 2022 | |
| Boston Scientific Corporation | $19.97 | 2022 | |
| Chiesi USA, INC. | $15.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaclyn Thoresz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.